These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30381900)

  • 1. Q817G mutation in phosphodiesterase type 5: Conformational analysis and dissociation profile of the inhibitor Tadalafil.
    Pires de Oliveira I; Lescano CH; De Nucci G
    Chem Biol Drug Des; 2019 Apr; 93(4):419-429. PubMed ID: 30381900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
    Zoraghi R; Francis SH; Corbin JD
    Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.
    Corbin JD; Zoraghi R; Francis SH
    Cell Signal; 2009 Dec; 21(12):1768-74. PubMed ID: 19665054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key features for designing phosphodiesterase-5 inhibitors.
    Chang TT; Huang HJ; Lee KJ; Yu HW; Chen HY; Tsai FJ; Sun MF; Chen CY
    J Biomol Struct Dyn; 2010 Dec; 28(3):309-21. PubMed ID: 20919747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
    Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
    J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
    Kayık G; Tüzün NŞ; Durdagi S
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.
    Cahill KB; Quade JH; Carleton KL; Cote RH
    J Biol Chem; 2012 Nov; 287(49):41406-16. PubMed ID: 23033484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
    Weeks JL; Corbin JD; Francis SH
    J Pharmacol Exp Ther; 2009 Oct; 331(1):133-41. PubMed ID: 19641165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
    Ahmed WS; Geethakumari AM; Biswas KH
    Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
    Bajraktari G; Burhenne J; Bugert P; Haefeli WE; Weiss J
    Biochem Pharmacol; 2017 Dec; 145():54-63. PubMed ID: 28964803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil.
    Bessay EP; Blount MA; Zoraghi R; Beasley A; Grimes KA; Francis SH; Corbin JD
    J Pharmacol Exp Ther; 2008 Apr; 325(1):62-8. PubMed ID: 18199808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile.
    Mieczkowski A; Speina E; Trzybiński D; Winiewska-Szajewska M; Wińska P; Borsuk EM; Podsiadła-Białoskórska M; Przygodzki T; Drabikowski K; Stanczyk L; Zhukov I; Watala C; Woźniak K
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33546456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
    Corbin JD; Francis SH
    Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.
    Chen CY
    J Biomol Struct Dyn; 2010 Apr; 27(5):627-40. PubMed ID: 20085380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
    Kayık G; Tüzün NŞ; Durdagi S
    J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
    Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
    J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5.
    Di Rocco G; Martinelli I; Pacifico S; Guerrini R; Cichero E; Fossa P; Franchini S; Cardarelli S; Giorgi M; Sola M; Ponterini G
    J Pharm Biomed Anal; 2018 Feb; 149():335-342. PubMed ID: 29132113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats.
    Wang L; Jia H; Tower RJ; Levine MA; Qin L
    Am J Physiol Endocrinol Metab; 2018 Oct; 315(4):E446-E453. PubMed ID: 29920215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.